Objectives:

Describe the risks and benefits of compounding PN solutions as 3-in-1 versus 2-in-1 admixtures in various populations
Identify factors affecting stability of 3-in-1 PN solutions and recognized conditions that may lead to destabilization
Evaluate the risks and benefits of using pre-mixed PN versus individualized PN admixtures for a given patient or facility
List the current recommendations from the CDC, the A.S.P.E.N. PN Safety Consensus recommendations, and current literature regarding the repackaging of IVFE and their appropriate hang times
Explain the rationale for repackaging IVFE in the neonatal population

Amber J. Verdell PharmD, BCPS, BCNSP, CNSC

Pharmacist, Olive View-UCLA Medical Center, Pasadena, CA